InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,306.40
(
0.48%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.42
(
1.12%
)
Bitcoin
61,550.29
(
1.21%
)
Post# of 146240
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

daBoze

Send PM Follow Ignore
Followers 7
Posts 1189
Boards Moderated 0
Alias Born 02/17/2009

daBoze

Re: TheDane post# 53215

Thursday, 08/04/2011 1:58:49 PM

Thursday, August 04, 2011 1:58:49 PM

Post# of 146240
Dendreon has fallen 64% on slow sales of its prostate drug "Provenge." The biotech market is off over 4%. The company blames the slowness on Doctor's reluctance to prescribe the $93,000, three infusion, regimen, fearing non-payment by insurance companies. Medicare agreed to cover the drug on June 30.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NNVC News
More NNVC News
InvestorsHub NewsWire

VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM

North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM

Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM

POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM

HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM

Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!